Categories: News

THE ADECCO GROUP Q3 2025 RESULTS

AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

- Advertisement -

Strong share gains, good growth and improved profit margin

- Advertisement -

ZURICH, Nov. 6, 2025 /PRNewswire/ —

- Advertisement -

 

- Advertisement -

HIGHLIGHTS

- Advertisement -
  • Further strong market share gains, Group +375 bps and Adecco +300 bps
  • Group revenues +3.4% yoy, and +3.0% qoq, with all GBUs improving sequentially
  • Adecco GBU revenues +4.5% yoy; Europe returned to growth; Americas +20% yoy, APAC +9% yoy
  • Akkodis GBU revenues -3% yoy; German turnaround progressing well
  • LHH GBU revenues +4% yoy, led by CT +9% yoy, Ezra +59% yoy
  • Healthy 19.2% gross margin, -10 bps yoy organic, and +30 bps sequentially, reflecting business mix, firm pricing
  • Solid 3.4% EBITA margin excl. one-offs, +10 bps yoy, reflecting good operating leverage, with productivity +8% yoy
  • Operating income €160 million, +2% yoy; Net income €89 million, -2% yoy
  • Basic EPS €0.53; Adjusted EPS €0.67
  • Strong 110% LTM cash conversion; solid operating cash flow of €200 million, up €79 million yoy
  • ND/EBITDA -0.3x qoq, with net debt €220 million lower yoy

Denis Machuel, Adecco Group CEO, commented:

- Advertisement -

“Our positive trajectory has continued in mixed markets, with further market share gains and good growth. We have improved margins by 90 basis points compared to the last quarter, demonstrating strong operating leverage. We thank our teams for yet another quarter of rigorous execution. We remain on track to reach our full year margin commitment.

- Advertisement -

“We are particularly pleased with Adecco’s strong results, with solid growth across multiple regions. Akkodis improved sequentially with our German turnaround progressing well. LHH returned to growth, supported by continued strength from Career Transition.

- Advertisement -

“We look forward to sharing the evolution of our strategy and detailed value creation plans at our Capital Markets Day in London on 26 November.”

- Advertisement -

Full Press Release

- Advertisement -

Webcast Details | Investors & Analysts

- Advertisement -

For further information, please contact:

- Advertisement -


Investor Relations


investor.relations@adeccogroup.com


+41 (0)44 878 88 88


Press Office


media@adeccogroup.com


+41 (0) 79 876 09 21

Logo: https://mma.prnewswire.com/media/2608173/5604293/The_Adecco_Group_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/the-adecco-group-q3-2025-results-302606146.html

- Advertisement -

Recent Posts

Blockchain.com Unveils Highly Anticipated Crypto-Backed Loans, Bringing Borrowing To Crypto Holders Worldwide

The company launches in-house lending for global users starting at 1.9%, delivering one of the…

6 hours ago

Artmarket.com: The Artprice Manifesto: 22 Rules for a Regulated and Transparent Art Market in the Age of AI

Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS, May 14, 2026…

6 hours ago

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

15 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

15 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

15 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

15 hours ago